(Q41880272)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

title

Changes in blood eosinophilia during omalizumab therapy as a predictor of asthma exacerbation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Mateusz Lukaszyk

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Robert Milewski

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Anna Bodzenta-Lukaszyk

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Roman Skiepko

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Wojciech Budny

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Urszula Skiepko

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

publication date

22 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

Postępy Dermatologii i Alergologii

22 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

page(s)

305-309

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults

22 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

The activated eosinophil in allergy and asthma.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

Effect of omalizumab on peripheral blood eosinophilia in allergic asthma.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221351

Omalizumab for asthma: pharmacology and clinical profile

18 August 2018

1 reference

12 December 2020

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

1 reference

12 December 2020

Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy

1 reference

12 December 2020

Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society

1 reference

12 December 2020

Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide in Adults and Children—1999

1 reference

12 December 2020

Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma

1 reference

12 December 2020

Identifiers

DOI

10.5114/PDIA.2014.40973

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

PubMed publication ID

25395927

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25395927%20AND%20SRC:MED&resulttype=core&format=json